Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

This study found that women with PCOS have higher total PSA levels than controls, and the total PSA level correlates positively with testosterone and free androgen index.

In this research, most cases of mammary and extramammary Paget disease were reported to express PRAME, expanding the understanding of its presence in cutaneous epithelial tumors, though its diagnostic utility is limited by overlap with other conditions.

This study found that MPZL3 plays a crucial role in controlling sebaceous gland size and sebocyte proliferation in mice and humans, implicating its potential involvement in skin disorders like acne and psoriasis.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

In this study, PSA levels were significantly lower among African-American men with higher C-peptide levels and Caucasian men with higher HbA1c levels, suggesting a link between metabolic markers and prostate cancer detection.

This study indicates that MPZL3 negatively regulates sebaceous gland size in mice by controlling sebocyte proliferation, with implications for disorders like acne and psoriasis.

This study found that increased PSA levels in women with hyperandrogenism may serve as a diagnostic marker, comparable to free testosterone levels.

In this study, researchers found that deficiencies in Gsdma1/2/3 significantly inhibited the initiation and progression of cutaneous squamous cell carcinoma (cSCC) in mice, suggesting GSDMA's role in promoting cSCC proliferation and its potential as a therapeutic target.

This review discusses the potential use of prostate specific antigen as a diagnostic marker for hyperandrogenism in polycystic ovary syndrome but reports no new clinical results and calls for further research.

This review re-evaluates the role of Serum Prostate Specific Antigen in prostate cancer diagnosis, suggesting it is most reliable for detecting cancer recurrences after treatment.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

This study identified a new isozyme, 5α-reductase-3, at the mRNA level in human prostate tissue, but its protein expression and cellular localization remain unclear.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This study found that men with a cutaneous melanoma diagnosis had an increased risk of subsequently being diagnosed with prostate cancer compared to those without melanoma.

This study suggests that using the International Psoriasis Council's classification, which includes body surface area, special areas, and treatment history, may identify more candidates for systemic therapy than by body surface area alone.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

PRAME helps distinguish between benign and malignant skin cells in most cases.

The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.

This study found that among male Han Chinese, a higher polygenic risk score was linked to increased risk and poorer treatment outcomes for benign prostatic hyperplasia.

This study investigated genetic and epigenetic markers for prostate cancer, reporting that certain genotype combinations may influence cancer risk or protection and identifying GSTP1 promoter methylation as a strong prognostic and diagnostic marker linked to tumor aggressiveness.

Polygenic Score can help predict severe psoriasis and psoriatic arthritis.

This study found that testosterone replacement therapy, especially intramuscular administration, significantly increased PSA levels compared to placebo, while a significant correlation between PSA and testosterone was observed in non-BPH patients.

This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.

This study found that mrp/plf-mRNA expression in murine skin increases in response to different tumor promoters, suggesting its potential as a short-term biomarker for chemical carcinogenesis.

This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.